TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05485818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose
Description: 12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle Dose
Description: 12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose
Description: 12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 subjects will be randomly assigned to the placebo for 7 days
Study: NCT01290003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-Tazobactam and Amikacin
Description: Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
Study: NCT02747394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Working Memory Training

Intervention type: OTHER
Group type: OTHER
Intervention: Working Memory Training
Study: NCT02262026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg AZD0530
Description: Randomized to receive 125 mg of AZD0530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg AZD0530
Description: Randomized to receive 125 mg of AZD0530
Study: NCT03758391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flipped Classroom education
Description: Fellows will receive GI/Bilirubin education in a flipped classroom format.
Study: NCT01303796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: Oral sapacitabine capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Decitabine intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine intravenous
Study: NCT02262026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg AZD0530
Description: Randomized to receive 125 mg of AZD0530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03775265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study: NCT02262026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02234713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Attention Control
Study: NCT01541904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-118 Ophthalmic Solution 0.015%
Description: PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-118 Ophthalmic Solution 0.015 %
Description: PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
Study: NCT01541904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-118 Ophthalmic Solution 0.020 %
Description: PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-118 Ophthalmic Solution 0.020 %
Description: PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo Ophthalmic Solution applied qd during 21 days
Study: NCT00603096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare
Description: The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare
Description: The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
Study: NCT04181008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride Nasal Spray
Study: NCT03775265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study: NCT04181008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride Nasal Spray
Study: NCT03305588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unframed Virtual Cone
Description: The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
Study: NCT03302884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological sampling
Description: Tumor and blood samples
Study: NCT03316287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid
Description: Smart hearing aid to allow collection of real time hearing aid usage data

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid
Description: Smart hearing aid to allow collection of real time hearing aid usage data

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone
Description: Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone
Description: Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor
Description: Wearable biosensor for the collection of physiological data
Study: NCT02387333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion
Description: After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin.
Study: NCT02532972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Med-el MAESTRO Cochlear Implant with Flex 28 electrode array
Description: Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
Study: NCT02387333

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ileal conduit urinary diversion
Description: In this group, no mesh will be applied with ileal conduit urinary diversion
Study: NCT02379988

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Verify radiation dose to heart and lung
Description: This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
Study: NCT01213459

Intervention type: PROCEDURE
Intervention: Cervical samples
Description: Human papillomavirus detection and typing in cervical samples.

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire completion
Study: NCT03791281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASIS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Study: NCT00520702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: 66 Gy in 33 Daily Fractions at 2 Gy per fraction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: 66 Gy in 33 Daily Fractions at 2 Gy per fraction.
Study: NCT00431444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo intravenous (i.v.) infusion
Study: NCT03213938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.~Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.~Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks).
Study: NCT01794078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline 400 mg
Description: Xanthine derivative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline 400 mg
Description: Xanthine derivative
Study: NCT03983759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab maintenance
Description: the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
Study: NCT01794078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Description: Endothelin receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Description: Endothelin receptor antagonist
Study: NCT02029469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ascension HRA device
Description: Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
Study: NCT01794078

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04536116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality headset
Description: MRI simulation with a Virtual Reality headset
Study: NCT02438098

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban 10 mg
Description: Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
Study: NCT00717691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metatarsophalangeal Extension Dynasplint System
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
Study: NCT01990508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted beverage education and financial incentives

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Traffic-light labeling of all beverages in store
Description: All beverages in the supermarket will be labeled as red, yellow, or green

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traffic-light labeling of all beverages in store
Description: All beverages in the supermarket will be labeled as red, yellow, or green
Study: NCT00635869

Intervention type: BEHAVIORAL
Intervention: ARCC standard information
Description: EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs

Intervention type: BEHAVIORAL
Intervention: ARCC enhanced
Description: same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
Study: NCT00717691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard of Care
Description: The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
Study: NCT01596400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron transdermal system
Description: patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron IV
Description: IV
Study: NCT00635869

Intervention type: BEHAVIORAL
Intervention: Placebo
Description: didactic education sessions on physical assessment
Study: NCT04155905

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fistulotomy and marsupialization of wound edges
Description: after defining the fistulous track it was laid open (marsupialization) was done together with marsupialization of the wound edge with vicryl 3\\0 sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fistulotomy
Description: after defining the fistulous track it was laid open (marsupialization)
Study: NCT01339819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Patients assigned to this group will receive Dabigatran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: Patients assigned to this group will receive Phenprocoumon
Study: NCT00918775

Intervention type: OTHER
Intervention: Follow-Up Care
Description: Undergo follow-up

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01642498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROX COUPLER
Description: The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
Study: NCT02558036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C-Mac D-Blade Videolaryngoscope
Description: Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
Study: NCT03568175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion, 2.0 mg/kg/week
Study: NCT02877641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Given PO
Study: NCT02558036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C-Mac D-Blade Videolaryngoscope
Description: Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
Study: NCT02877641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03709706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lete-cel
Description: lete-cel will be administered to eligible participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lete-cel
Description: lete-cel will be administered to eligible participants.
Study: NCT02558036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: King Vision Videolaryngoscope
Description: Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: King Vision Videolaryngoscope
Description: Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
Study: NCT03400865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ/CQ and CAB combined treatment
Description: Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
Study: NCT03181217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 0
Description: 300 ml tap water at 0 ºC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 0
Description: 300 ml tap water at 0 ºC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 0
Description: 300 ml tap water at 0 ºC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 0
Description: 300 ml tap water at 0 ºC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 22
Description: 300 ml tap water at 22 ºC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 22
Description: 300 ml tap water at 22 ºC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 22
Description: 300 ml tap water at 22 ºC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 22
Description: 300 ml tap water at 22 ºC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose 0
Description: 300 ml tap water at 0 ºC with 75 grams of glucose added

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose 0
Description: 300 ml tap water at 0 ºC with 75 grams of glucose added

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose 0
Description: 300 ml tap water at 0 ºC with 75 grams of glucose added

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose 0
Description: 300 ml tap water at 0 ºC with 75 grams of glucose added

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose 22
Description: 300 ml tap water at 22 ºC with 75 grams of glucose added
Study: NCT05177978

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine
Description: Phosphatidylserine containing supplement (2 x chewable gummies/day; Total daily dose of 100 mg elemental phosphatidylserine)